Tuesday September 19th 2017

Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the…

Multiple sclerosis (MS) has a significant impact on health-related quality of life (HRQoL) with symptoms adversely affecting many aspects of everyday living. BG-12 (dimethyl fumarate) demonstrated significant efficacy in the phase III studies DEFINE and CONFIRM in patients with relapsing–remitting MS. In CONFIRM, HRQoL was worse in patients with greater disability at baseline, and who relapsed during the study, and improved with BG-12 treatment. Mean Short Form-36 Physical Component Summary scores for BG-12 increased over 2 years and scores for placebo decreased. Coupled with clinical and neuroradiological benefits, these HRQoL results further support BG-12 as an effective oral treatment for relapsing MS. (Source: Multiple Sclerosis)

MedWorm Sponsor Message: Find the best Christmas Sales, Boxing Day Sales and January Sales here.

Original source:

Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the…

Leave a Comment

More from category

Scientists discover markers for progressive multiple sclerosis
Scientists discover markers for progressive multiple sclerosis

Scientists have uncovered two closely related cytokines -- molecules involved in cell communication and movement -- [Read More]

Study uncovers markers for severe form of multiple sclerosis
Study uncovers markers for severe form of multiple sclerosis

Scientists have uncovered two molecules involved in cell communication and movement that may explain why some people [Read More]

Costly drugs to weigh on U.S. employers’ expenses in 2018: survey
Costly drugs to weigh on U.S. employers’ expenses in 2018: survey

(Reuters) - U.S. employers are bracing for higher health care expenses in 2018 as spending on new drugs to treat [Read More]

TG Therapeutics commences enrolment for Phase III multiple sclerosis trials
TG Therapeutics commences enrolment for Phase III multiple sclerosis trials

US-based biopharmaceutical firm TG Therapeutics has commenced enrolment for the Phase III ULTIMATE clinical programme [Read More]

Therapy could offer new hope for MS patients
Therapy could offer new hope for MS patients

Multiple sclerosis sufferer Roy Palmer and his wife Helen (pictured) are desperate for him to be able to walk again. [Read More]